Prescriber Resources

THALOMID® (thalidomide) in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).

THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.

THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

Enrolling in THALOMID REMS®

In order to prescribe THALOMID, you must enroll in the THALOMID REMS® program (formerly known as the
S.T.E.P.S.® program) and agree to follow the requirements of the program. You can enroll by visiting CelgeneRiskManagement.com, a website that allows prescribers to handle the REMS process for all of the Celgene REMS programs. You can also download the Prescriber Enrollment Form below and fax it to Celgene Customer Care at 1-888-432-9325.

Prescribing THALOMID for your patients

In order to receive THALOMID, your patients must also be enrolled in the THALOMID REMS® program. You can enroll your patients and fill out a prescription form using CelgeneRiskManagement.com. You and your patients can also complete your mandatory confidential surveys there.

Additionally, you can also enroll your patients and write prescriptions by downloading the Desktop Software and installing it on your computer.

Learning more about THALOMID REMS®

For additional information about the THALOMID REMS® program, please see the educational materials below.


Please report adverse drug experiences that are suspected to be associated with the use of THALOMID and any suspected pregnancy occurring during the treatment with THALOMID to Celgene using any of the following methods:

REPORTING TO CELGENE

Email:

Telephone:

1-908-673-9667

Toll-free:

1-800-640-7854 (Global Drug Safety & Risk Management) or
1-888-423-5436 (Celgene Customer Care Center)

Fax:

1-908-673-9115

Mail to:

Global Drug Safety & Risk Management
Celgene Corporation
556 Morris Avenue
Building S12
Summit, New Jersey 07901

REPORTING TO THE FDA

Adverse drug experiences that are suspected to be associated with the use of THALOMID and
any suspected pregnancy occurring during the treatment with THALOMID may also be reported
to the FDA MedWatch Reporting System using any of the following methods:

Online:

Telephone:

1-800-FDA-1088

Fax:

1-800-FDA-0178

Mail to:

MedWatch
5600 Fishers Lane
Rockville, MD 20852-9787

For additional information about the THALOMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: